Vicarious Surgical Confronts NYSE Delisting Notice

Vicarious Surgical's Beta 2 robotic surgery system. | Credit: Vicarious Surgical

Vicarious Surgical (NYSE:RBOT) has been notified by the New York Stock Exchange (NYSE) that it is initiating procedures to delist the company's stock.

The surgical robotics company, based in Waltham, Massachusetts, received the formal notice from the exchange on March 3, 2026. Consequently, trading of the company's shares was suspended at the close of the market that day.

RBOT shares are currently priced at $1.92 each ahead of the NYSE market opening today.

Vicarious stated that the NYSE made its determination because the company's stock failed to meet the continued listing requirement. This standard mandates that listed companies maintain a minimum average global market capitalization of $15 million over a consecutive 30-trading-day period.

The company has a 10-business-day window to appeal the decision following receipt of the notice. Vicarious indicated it is currently evaluating a potential appeal. In the interim, the company has secured approval for its stock to be quoted on the OTCIQ market tier, operated by OTC Markets Group. It anticipates its common stock will begin trading on that platform at the market open today, March 4, 2026, and plans to continue using the "RBOT" ticker symbol.

This marks a second confrontation with delisting for the company, which also fell below NYSE standards in 2023. It subsequently executed a reverse stock split in mid-2024 to regain compliance.

Recent developments at Vicarious Surgical

The potential delisting occurs at a pivotal moment for Vicarious. The company has been progressing with its surgical robotics platform for several years, though the journey has encountered multiple delays.

The Vicarious robot is engineered to improve the efficiency of surgical operations. The company initially targeted the first-in-human trials for mid-2025 but postponed the timeline in November 2023. By March 2024, Vicarious outlined a revised plan to prepare its "V1.0" system for an FDA submission in early to mid-fiscal 2026.

In late 2024, the company announced intentions to conduct a year-end cadaver lab for the V1.0 system. This would be followed by verification, validation, and optimization work prior to formal clinical trials. A new hospital partnership was revealed in May 2025, representing a step toward deploying the surgical robot. However, in August of that year, Vicarious decided to defer the start of clinical trials to allow for further robot development, setting a target for a final design freeze by the end of 2026.

Earlier this year, the company successfully conducted an in-vivo porcine lab study for its robot. According to Vicarious, this achievement supports its ongoing progress toward the planned system design freeze scheduled for late 2026.